There is no reliable evidence to support avoiding radioactive iodine treatment for thyroid cancer based on this study, because the study was flawed, had no comparison group, and was later retracted for fraudulent peer review.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether I-131 therapy increases the risk of secondary malignancies or mortality in PTC patients compared to no I-131, based on high-quality long-term outcome data.
A systematic review and meta-analysis of all prospective cohort studies and randomized trials comparing 10-year survival, recurrence, and secondary cancer incidence in PTC patients with and without I-131, with adjustment for risk stratification, age, and radiation dose.
Whether I-131 therapy improves survival or reduces recurrence in intermediate-risk PTC patients compared to observation alone.
A multicenter, double-blind RCT of 1,000 intermediate-risk PTC patients randomized to receive I-131 (100 mCi) or no I-131 after total thyroidectomy, with primary endpoints of disease-free survival and secondary malignancy incidence at 10 years.
Whether I-131 exposure is associated with increased risk of secondary cancers in PTC survivors over 15 years.
A national cohort study of 50,000 PTC survivors in the U.S. and Europe, linked to cancer registries and radiation exposure records, comparing secondary cancer incidence in those who received I-131 versus those who did not, adjusting for age, sex, and tumor stage.
Whether PTC survivors who developed secondary malignancies were more likely to have received I-131 than those who did not.
A case-control study of 500 PTC survivors with secondary cancers and 1,000 without, matched for age, sex, and tumor stage, assessing I-131 exposure history, cumulative dose, and timing relative to cancer diagnosis.
Whether expert consensus supports or opposes I-131 use in low-risk PTC based on current evidence.
A Delphi consensus process involving 50 endocrinologists and nuclear medicine specialists reviewing all available evidence on I-131 risks and benefits in PTC, with structured voting on clinical recommendations.